TCM
VTGN icon

TCG Crossover Management’s VistaGen Therapeutics VTGN Stock Holding History

TCG Crossover Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,676,580
Closed -$1.53M – 60
2026
Q1 		$1.53M Hold
2,676,580
– – 0.04% 49
2025
Q4 		$1.77M Hold
2,676,580
– – 0.06% 43
2025
Q3 		$9.5M Hold
2,676,580
– – 0.47% 33
2025
Q2 		$5.35M Hold
2,676,580
– – 0.61% 29
2025
Q1 		$6.69M Hold
2,676,580
– – 0.91% 29
2024
Q4 		$7.9M Hold
2,676,580
– – 0.77% 33
2024
Q3 		$8.06M Hold
2,676,580
– – 0.68% 27
2024
Q2 		$9.31M Hold
2,676,580
– – 0.97% 23
2024
Q1 		$14.1M Hold
2,676,580
– – 1.12% 25
2023
Q4 		$13.8M Buy
+2,676,580
New +$10.1M 1.53% 21

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

TCG Crossover Management's VTGN Position: Q2 2026 in Review

TCG Crossover Management sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 2,676,580 shares — an estimated $1.53M sold.

TCG Crossover Management first reported a position in VTGN in Q4 2023 and held it in 10 quarters. The position peaked at $14.1M in Q1 2024. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • TCG Crossover Management reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TCG Crossover Management sold 2,676,580 VistaGen Therapeutics shares in Q2 2026, an estimated $1.53M.
  • TCG Crossover Management first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 10 quarters.
  • TCG Crossover Management's VistaGen Therapeutics position peaked at $14.1M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.